Targeting the B Cell Lineage in IgG4-Related Disease

  • John H. Stone


Despite the elevated serum concentration of IgG4 in many patients and the disproportionate number of IgG4+ plasma cells within the affected tissues that constitute essentially a sine qua non of IgG4-related disease, serum IgG4 itself appears to be a reactive phenomenon rather than the primary disease driver. Recent investigations have focused on the interactions between cells of the B cell lineage and a novel CD4+ cytotoxic T cell that is capable of promoting fibrosis.


Serum IgG4 Lacrimal Gland Cell Depletion Serum IgG4 Concentration Elevated Serum Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Wallace ZS, Mattoo H, Carruthers M, Mahajan VS, Della Torre E, Lee H, Kulikova M, Deshpande V, Pillai S, Stone JH. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations. Ann Rheum Dis. 2015;74:190–5.Google Scholar
  2. 2.
    Mattoo H, Mahajan VS, Della-Torre E, Sekigami Y, Carruthers M, Wallace ZS, Deshpande V, Stone JH, Pillai S. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG-related disease. J Allergy Clin Immunol. 2014;134:679–87.Google Scholar
  3. 3.
    Yamamoto M, Takahashi H, Tabeya T, Suzuki C, Naishiro Y, Ishigami K, et al. Risk of malignancies in IgG4-related disease. Mod Rheumatol. 2015;22(3):414–8.CrossRefGoogle Scholar
  4. 4.
    Wallace ZS, Wallace CJ, Lu N, Choi HK, Stone JH. IgG4-related disease is associated with a history of invasive malignancy. Arthritis Rheumatol. 2016 (in press).Google Scholar
  5. 5.
    Stone JH, Merkel PA, Spiera R, et al. Rituximab compared with cyclophosphamide for remission induction in ANCA-associated vasculitis. N Engl J Med. 2010;363:221–32.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ahmed AR, Spigelman X, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to swift decline of serum IgG4 levels and prompt clinical improvement in IgG4-related disease. Arthritis Rheum. 2010;62:1755–62.CrossRefPubMedGoogle Scholar
  8. 8.
    Khosroshahi A, Carruthers MD, Deshpande V, et al. Rituximab for the treatment of IgG4-related systemic disease: lessons from a series of ten consecutive cases. Medicine (Baltimore). 2012;91:57–66.CrossRefGoogle Scholar
  9. 9.
    Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015;74:1171–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Wallace ZS, Mattoo H, Mahajan VS, Kulikova M, Lu L, Deshpande V, Choi HK, Pillai S, Stone JH. Predictors of disease relapse in IgG4-related disease. Rheumatology. 2016;55(6):1000–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Mattoo H, Mahajan VS, Maehara T, Deshpande V, Della-Torre E, Wallace ZS, Kulikova M, Drijvers JM, Daccache J, Carruthers MN, Castellino F, Stone JR, Stone JH, Pillai S. Clonal expansion of CD4 cytotoxic T lymphocytes in patients with IgG-related disease. J Allergy Clin Immunol. 2016.Google Scholar
  12. 12.
    Dellatorre E, Feeney E, Deshpande V, Mattoo H, Mahajan V, Kulikova M, Wallace ZS, Carruthers M, Chung RT, Pillai S, Stone JH. B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. Ann Rheum Dis. 2015;74:2236–43.Google Scholar

Copyright information

© Springer Japan 2016

Authors and Affiliations

  1. 1.Rheumatology Clinic/Yawkey 2Massachusetts General HospitalBostonUSA

Personalised recommendations